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Tuberculosis is a treatable and preventable disease; however, tuberculosis 
continues to be a leading cause of morbidity and mortality around the globe. Per the 
World Health Organization (2016), tuberculosis (TB) disease was responsible for 10.4 
million illnesses and 1.8 million deaths in 2015.  Strategic plans by public health entities 
are continually under development at the global, national, and state levels to utilize 
innovative methods for identifying, treating, and preventing transmission of TB.  Newer 
testing technologies and recommendations, are available for screening patients at risk for 
developing TB disease, creating an opportunity for development of a new tuberculosis 
screening and testing clinical protocol    
The purpose of this project was to develop a point-of-care clinical protocol that 
would assist public health workers and primary care providers with screening and testing 
for tuberculosis.  An online survey was developed to assess the effectiveness, efficiency, 
and evidence-based content of the protocol.  The protocol and survey were sent to 229 
subject-matter experts for review and survey feedback. There were 25 responses to the 
online survey. Overall, 79.6% of the participants thought the protocol was effective, 
76.5% agreed it was efficient, and 85.2% stated it was evidence-based.  Although the 
response rate was low, respondents represented a variety of health disciplines, were 
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experienced in TB screening, and provided specific feedback.  The point-of-care 
evidence-based screening and testing protocol has potential to provide effective and 
efficient guidance in TB screening in public health, community health, and primary care 
clinics.   
Keywords:  interferon gamma release assay, latent tuberculosis infection, 
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New tuberculosis testing technologies have been introduced in the United States 
within the past 15 years.  Guidelines for interferon gamma release assay (IGRA) testing 
for detection of mycobacterium tuberculosis were published by the Centers for Disease 
Control (CDC) in the 2010 Morbidity and Mortality Weekly Report (MMWR; Mazurek et 
al., 2010).  In 2016, The U.S. Preventative Services Task Force (USPSTF) published its 
final recommendation for tuberculosis screening of at-risk populations.  In January 2017, 
new clinical practice guidelines for diagnosing tuberculosis were published by the 
American Thoracic Society and the CDC (Lewinsohn et al., 2017).   
The other widely accepted test available to detect mycobacterium tuberculosis is 
the tuberculin skin test (TST) developed by Von Pirquet and Mantoux in 1907-1908 
(CDC, 1982).  Given the original skin test is well over 100 years old, new developments 
and technology to detect mycobacterium tuberculosis are long overdue. Treatment of 
tuberculosis (TB) is becoming increasingly challenging as drug resistance is also on the 
rise.  It is imperative for providers to accurately diagnose and treat both latent and active 
TB to avoid further increasing drug resistance, save limited healthcare resources, and 
provide high quality care for patients.  To accurately diagnose TB, it is important to 
understand which test is best for the patient and how to interpret the results.  
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 In September 2016, the USPSTF finalized a recommendation statement for latent 
tuberculosis screening.  A grade B was assigned for screening populations at increased 
risk of latent tuberculosis infection.  Grade B means there is great certainty of a moderate 
to substantial net benefit and screening at-risk populations is recommended (USPSTF, 
2016).  An evidence report supporting the USPSTF recommendations was published in 
2016 by Kahwati et al.  
 In January 2017, the most recent guidelines available for diagnosing tuberculosis 
were published by the American Thoracic Society, Infectious Diseases Society of 
America, Centers for Disease Control and Prevention, and Clinical Practice Guidelines 
(Lewinsohn et al., 2017).  These recommended guidelines also supported screening 
populations at risk for tuberculosis.  Additionally, preferences for the IGRA test over TST 
were established in most clinical situations.  The exception to this was if the IGRA test 
was too expensive, too burdensome, or not available.  While these new guidelines did not 
aim to impose a strict standard, they were meant to guide the clinician’s decision-making 
based upon available evidence.  Often many unique patient factors are associated with 
clinical decision-making for TB screening and testing (Lewinsohn et al., 2017). 
 The purpose of this project was to design and implement a user-friendly clinical 
protocol to assist providers in deciding which tuberculosis test would be most appropriate 
based upon the patient’s clinical situation, risk factors, available financial resources, and 
reason for screening.  In addition, a decision-making tool was developed to assist 
providers in determining clinical decision-making following positive, negative, or 
indeterminate test results based upon the most current evidence-based guidelines for both 
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the TST and the IGRA test.  The most recent guidelines for TB diagnosis supported the 
clinical protocol and decision-making tool (Lewinsohn et al., 2017). 
Background and Significance 
The United Nations Millennium Development Goals were committed to stopping 
the TB epidemic by the end of 2015 through an initiative named the Stop TB Partnership.  
This initiative was first developed in 2000.  The efforts resulted in saving 43 million lives 
between 2000-2014.  Not all the objectives were met and progress toward TB elimination 
showed a slow decline between 2000-2014 (Stop TB Partnership, 2015).  Barriers were 
identified that contributed to slow progression toward TB elimination: poor health 
systems, poverty, malnutrition, migration, aging populations, smoking, and chronic health 
conditions.  There was also a lack of resources available to perform the optimal work 
needed to fulfill the goal (Stop TB Partnership, 2015).  In 2014, The World Health 
Organization (2015a) created a renewed initiative called the End TB Strategy.  This 
updated initiative aimed to address barriers to progress previously identified.   
Ending the TB epidemic requires identification of key populations most at risk for 
developing TB disease.  Medically underserved populations, individuals with increased 
risk to TB exposure, and certain individuals who are immunocompromised due to certain 
health issues and behaviors are at the highest risk.  Target populations differ between 
countries so it is the responsibility of each country to identify their own at-risk 
populations.  The updated initiative aims to treat 90% of the population with TB disease, 
increase care for 90% of all vulnerable populations, and reach a 90% cure rate for all 
people diagnosed with TB (Stop TB Partnership, 2015). 
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Elimination of tuberculosis in the United States is dependent upon implementing 
strategic plans to screen, test, and treat individuals at increased risk for developing active 
TB disease.  Screening and treatment of Latent TB Infection (LTBI) is the primary 
method used for eliminating TB in the United States (Linas, Wong, Freedberg, & 
Horsburgh, 2011).  In both public health and primary care settings, it is important to 
effectively screen for, test, and treat LTBI and active TB in a cost-effective manner. In the 
most recent statement written by the USPSTF (2016), a moderate benefit of screening for 
LTBI was noted in persons at increased risk for TB. 
 In addition to the TST, IGRA tests have been developed and are being used to test 
for LTBI and TB disease.  A wide variety of studies and literature have been published 
assessing reliability, usefulness, and cost-effectiveness of both tests in many populations 
at various risks for developing active TB (Linas et al, 2011).  Few resources have been 
found that compiled this information into a user-friendly, evidence-based, point-of-care, 
clinical decision-making protocol applicable to all persons with various TB risk factors.  
 Populations at risk for tuberculosis include immigrants; refugees; foreign born 
individuals from countries with a high prevalence of TB; immunocompromised 
individuals including those with HIV, diabetes, and chronic health issues; people who are 
homeless or in jail; individuals who inject drugs; and children and adults with recent 
exposure to active TB disease (Horsburgh & Rubin, 2011).  In addition to clearly 
identifying who should be tested for TB, providers must choose which test to use--the 
IGRA test or the TST.  It is important for the provider and/or clinic staff to know how to 
properly administer the test, interpret the results, and order additional diagnostic studies 




Resources and clinical guidelines are available to assist providers with clinical 
decision-making regarding tuberculosis screening and testing.  New guidelines for the 
preferred use of the IGRA test in certain populations and situations were published by the 
American Thoracic Society, Infectious Diseases Society of America, and Centers for 
Disease Control (Lewinsohn et al., 2017).  Several barriers were identified that 
contributed to provider resistance to utilizing new testing techniques.  One barrier 
identified leading to potential challenges with clinical decision-making regarding TB 
testing was a significant diversity in recommendations for IGRA testing in the literature. 
Denkinger, Dheda, and Pai (2011) identified four different testing approaches in 33 
different guidelines from 25 countries, the CDC, and American Academy of Pediatrics: 
(a) a two-step approach using the TST first followed by the IGRA test; (b) IGRA test only 
to replace the TST; (c) both the TST and the IGRA test together; and (d) either the TST or 
the IGRA test but not both.  With so many available choices for testing, providers might 
be challenged with which diagnostic test to use given the patient’s clinical situation.  
An additional challenge to clinical decision-making found in the literature was 
many studies focused on testing specific populations at risk for TB.  There were too many 
unique patient situations and risk factors to rely specifically on any one guideline for 
choosing the best TB diagnostic tool.  Valuable clinic time could potentially be lost while 
providers research best testing options for their patients.  The Infectious Diseases Society 
of America addressed this in its latest guidelines (Lewinsohn et al., 2017).  Both the TST 
and the IGRA are indirect tests with no ability to determine whether a patient has LTBI or 
active TB disease.  The test result itself provides limited information regarding next steps 
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for the patient and this can be challenging to providers.  The TST and IGRA sometimes 
result in false positives.  Newest recommendations by the Infectious Diseases Society of 
America suggested considering confirmatory testing in situations when the patient being 
tested is at low risk for TB and the initial test is positive (Lewinsohn et al., 2017).  The 
TST and the IGRA test do not distinguish active TB from latent TB.  Further assessment 
is needed in the form of symptom evaluation and chest radiograph in patients with 
positive test results (Lewinsohn et al., 2017).    
Gap Analysis and Opportunities 
 To move closer to TB elimination, it is important for providers to actively 
participate in testing high risk individuals for TB.  Currently, two types of approved tests 
are available for determining exposure to TB: the TST and the IGRA.  New evidence-
based guidelines are available to assist providers in choosing who should be tested and 
how testing should be done.  Clinical decision-making needs to be streamlined into an 
easy to access clinical tool to improve quality of care, effectiveness, and efficiency.  
 An opportunity exists to create a point-of-care clinical protocol for TB testing in 
support of the most current evidence-based guidelines for providers to use.  The goal of 
this project was to improve the quality of patient care and clinical efficiency through an 
easily accessible and user-friendly guide.  The main objective in relationship to the goal 
was to promote use of the best technology available for TB testing given a patient’s 
unique clinical situation.  The type of tool used for the clinical protocol was a decision-





Population, Intervention, Comparison,  
Outcome, and Time Question  
 For patients at high risk of TB disease presenting to the public health or primary 
care clinic (P), will implementing a clinical protocol to assist providers with TB testing 
decision-making (I) allow providers to choose the TB testing method that is most 
effective, efficient, and evidence-based leading to accurate clinical decision-making and 
proper identification of TB infection (O) at the time of the visit (T)? 
Theoretical Framework 
 The Stetler (2001) model of research utilization was used to implement the new 
clinical protocol and tool for TB testing. The Stetler model is a practitioner-based model 
used as a guide to implement evidence-based research knowledge into practice.  The type 
of research utilization appropriate for this project was to use research to create a process 
for routine problem-solving or clinical decision-making.  The Stetler model contains a 
series of steps that include critical-thinking and decision-making to facilitate use of 
research findings.  Criteria applicable to the studies include substantiating evidence, 
current practice related to desire to change, fitness of the findings to the clinical setting, 
and feasibility regarding risk compared to benefit.  The assumptions of the Stetler model 
include: 
1. The formal organization might or might not be involved in the individual’s 
utilization of research. 
2. Utilization might be instrumental, conceptual, and/or symbolic. 
3. Other types of evidence and/or non-research related information are likely to 
be combined with research findings to facilitate decision-making or problem 
solving. 
4. Internal and external factors can influence an individual’s or group’s view 
and use of evidence. 




6. Lack of knowledge and skills pertaining to research utilization and EBP can 
inhibit appropriate and effective use. (Stetler, 2001, p. 7) 
 
 The Stetler (2001) model contains five phases.  Phase I is preparation.  
Preparation includes searching, collecting, and sorting research evidence and defining the 
purpose and outcomes of the issue.  Phase II is validation, which involves performing a 
utilization-focused critique or synopsis of the issue.  If the synopsis is accepted, Phase III 
is the comparative evaluation/decision-making step.  Phase III incorporates Phase II 
findings into the setting, feasibility, substantiation of evidence, and current practice to 
consider application.  Phase IV is the translation/application step of the process and Phase 
V is the evaluation phase (Stetler, 2001). 
Literature Review 
 Several online databases were searched for research literature including Google 
Scholar, Cochrane, CDC.gov, and the general University of Northern Colorado library 
search engine.  Search terms used for literature included interferon gamma release assay, 
tuberculin skin test, latent tuberculosis infection, tuberculosis, tuberculosis testing and 
tuberculosis screening.  The terms recommendations and diagnosis of were also added to 
these search terms to narrow the focus of the search for articles containing testing 
recommendations and comparison of tests.  More than 1,000 articles were scanned for 
relevance to this project.  An iterative search was also done from paper and electronic 
references.  A total of 19 articles were chosen for the literature review based upon five 
different foci of information: evidence-based recommendations, test comparisons, clinical 
decision support tools, discordant results, and effectiveness.  A literature review table is 




Clinical Decision Support Tools 
 Only one article specifically addressed use of a clinical decision support tool for 
TB screening; however, this clinical support tool did not address which test would be 
most appropriate to choose given the patient’s risk.  The tool was a computer-based 
clinical decision support to alert the provider that testing was recommended (Steele et al., 
2005).  The CDC (2016) provided many articles and provider resources that were helpful 
for clinical decision-making for diagnosing TB including a mobile application for tablets 
and smart phones.  
Evidence-Based Recommendations 
 Three evidence-based recommendations published within the past 12 months 
were utilized to create the clinical protocol.  The Infectious Diseases Society of America 
(IDSA) guideline for diagnosing TB in adults and children was the most recent 
(Lewinsohn et al., 2017).  The guideline recommended testing with the IGRA test over 
the TST in most situations except for children under the age of five.  The TST was also an 
acceptable test if the IGRA was unavailable, too expensive, or too troublesome 
(Lewinsohn et al., 2017).  The USPSTF evidence report reviewed 72 studies and 
determined both the TST and IGRA were sensitive and specific for TB in countries with 
low TB burden like the United States (Kahwati et al., 2016).  Pai and Menzies (2017) 
offered TB recommendations for HIV-uninfected adults.  This article and other associated 
links in this article contained comparable recommendations to the IDSA and USPSTF.  
Test Effectiveness 
 Seven test comparison studies are included in the literature review.  The studies 
compared the two commercially available IGRA tests--QFT and T-SPOT--with each other 
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and/or the tuberculin skin test.  Kobashi et al. (2008) evaluated differences between the 
two commercially available blood tests for TB.  Their study determined blood tests were 
more useful than the TST in identifying patients with active TB disease.  One study 
compared TST with the QFT and Quantiferon-TB Gold test (QFT-G) and IGRA, resulting 
in the QFT-G being slightly more specific than the TST in Navy recruits (Mazurek, 
Zajdowicz et al., 2007).  A study done by Manusco et al. (2012) determined an 
insignificant statistical difference between the two commercially available IGRA tests 
and the TST in U.S. military recruits.  The two studies performed on military recruit 
subjects in the United States provided valuable information for test choice since most 
new military recruits are low risk for TB infection.  
 One study compared the TST with two commercially available IGRA tests in 
individuals with suspected TB (Mazurek, Weis et al., 2007).  In this study, all three tests 
had similar sensitivity.  Painter et al. (2013) compared the TST with QFT-G in immigrant 
populations vaccinated with bacillus Calmette–Guérin (BCG) vaccine.  The QFT-G 
sensitivity was 86.4% compared with a TST sensitivity of 52.3% in this population.  This 
study confirms the preference for the IGRA test over the TST in persons with the BCG 
vaccination.  Another study compared two IGRA tests (Higuchi et al., 2008).  This study 
resulted in the T-SPOT test being more sensitive (100%) than the QFT-G (87.2%) but the 
T-SPOT was less specific than the QFT at 83.3% and 98.8%, respectively (Higuchi et al., 
2008).  A systematic review of IGRA tests in comparison to the TST for diagnosis of 
active TB revealed the IGRA tests were more sensitive than the TST but not sensitive 
enough to use IGRA tests to rule out a diagnosis of active TB (Sester et al., 2010).  
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 Diagnosing TB infection is challenging.  Both IGRA tests and TST results might 
be falsely positive, falsely negative, or indeterminate.  Many factors influence discordant 
results.  Jeon et al. (2013) published a study that determined patients with high 
inflammation markers such as C-reactive protein, immune compromised patients, or older 
patients had a higher probability of indeterminate and false negative results with the QFT-
In Tube Gold IGRA test.  Another study reviewing literature from 33 different guidelines 
in 25 countries showed much diversity in TST and IGRA testing recommendations 
(Denkinger et al., 2011).  This study recommended more transparent, evidence-based 
guidelines for IGRA testing and noted a possible lack of disclosure of conflicts of interest 
with the commercial IGRA tests.  Lastly, a study was done regarding screening of Italian 
healthcare workers for TB infection (Olivieri et al., 2016).  Evidence in this study 
supported use of the IGRA test to confirm positive TST tests in this population.  The 
newest IDSA (Lewinsohn et al., 2017) guidelines also provided recommendations for 
considering additional confirmative testing with the IGRA after a positive TST in some 
clinical situations.  
Cost 
 Cost might be a contributing factor in test choice for some providers and clinics. 
Review of literature using the search terms resulted in two appropriate research articles 
containing information about testing specific high-risk populations with the IGRA test 
and/or TST to determine cost-effectiveness.  Pareek et al. (2012) conducted an 
observational study and economic analysis of tuberculosis screening in 231 immigrants 
using the TST and IGRA testing in the United Kingdom.  Using the IGRA test in 
immigrant populations might eliminate the need for a chest X-ray, which would improve 
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cost effectiveness of using the IGRA test over the TST.  Linas et al. (2011) indicated 
screening in some groups was more cost effective using the IGRA test over the TST in 
the United States.  These groups included foreign-born persons, individuals at high risk 
of TB reactivation, vulnerable populations (homeless, drug users, and prisoners), and 
patients with medical co-morbidities such as diabetes.  Data for this study were collected 
through CDC surveillance data and National Health and Nutrition Examination Survey 
estimates of positive TST prevalence (Linas et al., 2011).  U.S. census population 
estimates were used to determine equation variables.  Life expectancy gains were 
calculated comparing no screening at all with TST screening.  Screening with the TST 
resulted in a gain of 0.00-0.24 life months.  In comparison to TST screening, IGRA 
screening resulted in life expectancy gains of 0.00-0.01 life months (Linas et al., 2011). 
Articles like these are useful in determining the most cost-effective test choice in 

















 The objective for this project was to design and evaluate an easy to use clinical 
protocol for future implementation in primary care, public health, and community health 
clinics to assist clinicians with decision-making regarding the most effective, efficient, 
and evidence-based testing methods for latent and active tuberculosis based upon the 
patient’s identified risk factors for TB.  To support decision-making, guidance on test 
result interpretation and what to do if the results were indeterminate was provided.  The 
project assessed effectiveness and potential usefulness of the clinical protocol and, if 
possible, assessed for improvements in properly screening and testing individuals at risk 
for TB per evidence-based guidelines.  This protocol included a clinical decision-making 
algorithm, providing point of care assistance to health care providers.   
Project Plan 
 The project was planned in five phases while incorporating the Stetler (2001) 
model as a framework. Phase I was the preparation phase. Preparation for the project 
included reviewing, collecting, and summarizing clinical evidence.  A project site was 
selected to provide expert advice in development of the clinical protocol.  The optimal 
site was one that focused on general TB prevention activities, especially in high-risk 
populations.  Populations at risk for tuberculosis per the CDC (Lewinsohn et al., 2017) 
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definition included adults and children who were foreign-born, immunocompromised, 
homeless, incarcerated, underserved, or had recent exposure to TB disease including 
travelers potentially exposed to TB in countries where TB was prevalent. The clinic site 
was also familiar with TB testing technologies including both tuberculin skin tests and 
IGRA tests.  It was important to receive acceptance from the chosen site in development 
of the protocol and assessment of usefulness while avoiding disruption of staff daily work 
flow.   
 Phase II involved developing the clinical protocol utilizing the review of literature 
findings and expert opinions.  Expert opinions were provided by the clinical site staff 
experts along with experienced TB clinic providers and nurses.  The protocol was 
designed to enhance and complement current TB elimination objectives and assessment 
tools already designed by the state health department.  
 Phase III was the process of distributing the TB testing protocol to volunteer 
participants for review.  Participants included TB experts and staff at local health 
departments, community health clinics, and primary care providers.  The tool was e-
mailed to potential volunteer participants.  The state TB program assisted with 
distributing the protocol to volunteer participants.   
 Phase IV was the application phase of the project.  A Qualtrics survey was 
distributed to volunteer participants via e-mail.  The survey consisted of three focus areas 
that addressed components of the PICOT question.  The first section assessed potential 
clinical efficiency of the protocol while seeking feedback regarding the protocol design 
and content.  Another section sought information regarding current evidence-based 
choices of tuberculin skin tests and IGRA blood tests.  Information was sought regarding 
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how use of the protocol would assist with evidence-based TB care.  The survey also 
assessed the provider’s perception of clinical efficiency and effectiveness including why 
one test might be preferred over the other.  
 Phase V was the process of evaluating survey results.  If results of the survey 
revealed implementation of the protocol would improve clinical efficiency, effectiveness, 
and success with evidence-based TB clinical decision-making, future implementation of 
the protocol in clinical practice would be reasonable.  
Congruence of Organization’s Strategic Plan to Project 
 The Colorado Department of Public Health and Environment (CDPHE; 2017) 
provided guidance and recommended participants for protocol review.  This project 
supported the state health department’s strategic plan to eliminate TB.  The project 
committee consisted of one individual from the state health department along with two 
university faculty members with interest in infectious disease control, public health, 
and/or community health of patients in high risk populations.  
Timeline of Project Phases 
 The project timeline was just over one year in length beginning with development 
of the phenomenon of interest and ending with the final project defense.  The project 
began in January 2017 and ended in February 2018.  The research committee was chosen 
and the project proposal was written, proposed, and accepted by the end of spring 
semester of 2017. During summer semester of 2017, the clinic site was assessed and 
chosen for the pilot project.  Development of the clinical protocol began during the 
summer semester of 2017 with the objective of having the completely developed protocol 
available by mid-June 2017.  The project was implemented in October 2017.  Final 
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evaluation, completion, and defense of the project were completed in February, 2018, 
which was three months later than originally planned in the timeline.  A copy of the 
original timeline graph is provided in Appendix B.   
Resources 
 The budget for development of the clinical protocol was minimal.  The clinical 
protocol was developed utilizing technology currently available to the student at no cost. 
Evaluation of the project was conducted using Qualtrics software available through the 
university for no additional cost.  No expenses were anticipated for additional personnel 
to assist with project development.  The protocol and survey regarding the protocol were 
sent to participants in an electronic format via an e-mail attachment for printing on-site at 
the expense of the agency.  A budget of $800.00 was planned for travel and printing 
expenses, which were incurred by the Doctor of Nursing Practice (DNP) student.  
Ethical Considerations 
 Prior to project implementation, approval was obtained from the University of 
Northern Colorado’s Institutional Review Board (IRB) on September 21, 2017. An IRB 
approved consent form was developed and sent out with the recruitment letter, protocol, 
and link to the online survey.  Participation in the survey constituted consent; therefore, 
no signature was required (see Appendix C for the recruitment email, IRB approval letter, 
and consent form).  A statement of mutual agreement with the CDPHE was also 
developed and signed by the project committee prior to project implementation (see 











EVALUATION OF OBJECTIVES 
 
 
 The main objective was to design and evaluate a clinical-based protocol for 
determining the most appropriate TB testing method to use for specific patients based 
upon risk factors for having or acquiring TB and test feasibility.  The protocol included 
evidence-based guidance about how to interpret TB test results, what the next clinical 
steps should be if the test was positive or negative, and what to do if a test was 
indeterminate or borderline.  It was important to evaluate the effectiveness of test choice 
and clinical efficiency of the protocol.  A Qualtrics survey (see Appendix E) was 
administered to participants along with protocol distribution to include questions related 
to usefulness of the protocol and evidence-based guidance related to TB test result 
interpretation.  Data collection through the survey revealed preference for choice of test, 
if the guidance for test result management was helpful, and if use of the protocol 
encouraged practices to follow evidence-based guidelines.  The survey also assessed if 
the protocol would be helpful and practical for use in clinical sites.  
 Evaluation of the DNP project included assessment of the protocol regarding its 
helpfulness in decision-making.  The literature review revealed recommendations for 
preferred use of the IGRA test in some high-risk populations but it also revealed potential 
barriers to use of IGRA testing.  The survey assessed expert participants’ preferences of 
test choice and why one test might be chosen over the other.  Evaluation of the project is 
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Figure 1.  Model of evidence-based practice (Stetler, 2001, p. 276).  
 
Application of Evidence-Based Measures 
 The PICOT question served as a basis for project evaluation: For patients at high 
risk of TB disease presenting to the public health or primary care clinic, (P) will 
implementing a clinical protocol to assist providers with TB testing decision-making (I) 
allow providers to choose the TB testing method that is most effective, efficient, and 
evidence-based leading to accurate clinical decision-making and proper identification of 
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TB infection (O) at the time of the visit (T)?  Evaluation of the project focused on 
answering all components of the clinical question.  Evidence-based measures as 
recommended in the most recent guidelines were the basis of all clinical guidance 
provided in the protocol.  
Method of Analysis 
 Analysis of the evaluation data was descriptive in nature.  Data were organized 
with a focus on answering specific parts of the PICOT question:  effectiveness, 
efficiency, and evidence-based.  Both qualitative and quantitative data from the 
participant surveys were analyzed.  Analysis of the participant surveys regarding 
usefulness and practicality of the clinical tool was done by providing a descriptive report 
of the results obtained from the Qualtrics survey. 
Conclusion 
 The battle to eliminate TB continues to be a priority around the globe.  The 
initiative to stop TB involves several objectives including use of evidence-based testing 
techniques for diagnosing TB infection.  Newer technologies in the form of two 
commercially available IGRA tests are available for TB testing.  Opportunities exist to 
assist clinicians to make best evidence-based choices with well-designed point-of-care 
clinical protocols.  Information obtained from TB providers and staff about the clinical 
protocol helped determine the usefulness, efficiency, effectiveness, and utilization of best 
clinical evidence in TB testing techniques.  There may be future opportunities to 















 This chapter presents the results of the project including survey responses from 
subject matter experts.  The purpose of this project was to develop a TB clinical protocol 
for future use in public and community health clinics.  The protocol was designed to be 
clinically efficient, effective, and evidence-based.  Additionally, expert feedback was 
received evaluating the efficiency, effectiveness, and evidence-based content.  Case 
examples were presented in the survey for participants to test the protocol as it would be 
used in the clinical setting.  
 Although there were 25 total responses to the survey, not every participant 
answered each question.  Overall responses to the survey supported implementation of 
the TB protocol in practice.  A few participants felt too many barriers existed for the 
protocol to be useful in practice.  Many suggestions were provided to assist with 
modifying the protocol for improved efficiency, effectiveness, and evidence-based 
practice.  
Responses to Survey Questions 
The following paragraphs discuss the responses to each survey question including 
support or lack of concurrence based upon recent evidence-based guidelines.  Overall, 
most subject matter experts agreed the protocol was effective, efficient, and evidence-
based.  Feedback received for suggested additions, omissions, and changes to the 
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protocol pointed out several areas for improvement.  The responses also suggested 
changes that did not align with current evidence-based recommendations, leading to the 
necessity for further research prior to implementing suggested edits.   
Question One: Effectiveness of  
Screening Tool 
 The first question sought to address the effectiveness of the TB screening tool, 
testing protocol, and result guidelines.  Of 22 responses, 68.2% of the survey participants 
strongly agreed or agreed that the TB screening tool would be effective for 
implementation in practice in their clinic.  Approximately18.2% of the participants either 
somewhat agreed or neither agreed or disagreed as to the effectiveness of the screening 
tool.  A small percentage of participants (4.6%) strongly disagreed with the effectiveness 
of the screening tool.   
 There were 21 responses to Question #1 regarding the effectiveness of the TB 
testing protocol.  Most participants (80.9%) either strongly agreed, agreed, or somewhat 
agreed that the TB testing protocol would increase effectiveness of TB testing in their 
clinic.  The remaining 19.1% of the participants neither agreed or disagreed, disagreed, or 
strongly disagreed that the testing protocol would increase effectiveness of TB testing in 
their clinic. 
 Of the 21 responses regarding the effectiveness of the TB test results guidelines, 
76.2% strongly agreed, agreed, or somewhat agreed to the effectiveness of the guidelines 
in their clinic setting and 23.8% of the participants neither agreed, disagreed, or strongly 





Question Two: Protocol Evidence- 
Based? 
 
 Survey question #2 asked participants to determine if the TB screening tool, 
testing protocol, and result guidelines were evidence-based.  Of 22 responses, 85.5% 
strongly agreed, agreed, or somewhat agreed the TB screening tool was evidence-based. 
Only two participants (9.6%) somewhat disagreed or disagreed that the screening tool 
was evidence-based. Similarly, 85% of the participants strongly agreed, agreed, or 
somewhat agreed that both the TB testing protocol and results guidelines were evidence 
based.  No respondents strongly disagreed that the testing protocol and results guidelines 
were evidence-based. 
Question Three: Protocol Efficient? 
 Survey question #3 addressed the efficiency of the clinical protocol.  Overall, 
82.1% of the participants agreed the TB screening tool was efficient, 9.1% neither agreed 
or disagreed, and 14.2% somewhat disagreed, disagreed, or strongly disagreed that the 
TB screening tool would be efficient for clinical use.  The TB testing protocol and TB 
test result guidelines were tied at 76% strongly agreeing, agreeing, or somewhat agreeing 
that these components of the protocol would be efficient for use in the clinic setting.  
Question Four: Suggestions Regarding 
Additional Information 
 Survey question #4 sought suggestions for additional information to be added to 
the screening tool.  This question collected qualitative data from participants through an 
open text box for comments. A total of nine comments were received.  
 The first comment referred to the second screening question located on the 
tuberculosis screening questionnaire: Russia seems more specific than necessary. The 
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FSR such a Tajikistan, etc., would have similar risk. Wouldn't "countries in Asia and 
Eastern Europe work?”  The participant suggested limiting the question to include 
countries in Asia and Eastern Europe.  The screening question followed recommended 
screening guidelines from the CDC (2016), which specifically refers to individuals from 
Russia be recommended for TB testing.  It would be worth considering changing the 
question if the CDC recommends it in the future.  
 No additional changes were indicated in the second comment: Can’t think of 
anything. 
 The third comment reflected the efficiency of the entire TB protocol: I think the 
simplicity is part of its utility--we can always dig deeper as needed.  The participant 
understood the protocol provided a quick, point-of-care reference that could be further 
expanded upon as necessary.  
 In response to the fourth comment (Suggest removing all of Latin America when 
only BRAZIL is on any list of HBC. Makes everything else suspect), the CDC (2016) 
recommended individuals from most countries in Latin America be tested for TB.  
Twenty-two countries were listed on the World Health Organization’s (2015b) TB high 
burden list: Afghanistan, Bangladesh, Brazil, Cambodia, China, DR Congo, Ethiopia, 
India, Indonesia, Kenya, Mozambique, Myanmar, Nigeria, Pakistan, the Philippines, 
Russian Federation, South Africa, Thailand, Uganda, UR Tanzania, Viet Nam, and 
Zimbabwe.  It was estimated in the year 2000 that 80% of new TB cases in the world 
originated in these countries (World Health Organization, 2015b).  It is true that Brazil is 
the only Latin American country on the high burden list; however, the CDC still 
recommends screening individuals from most Latin American countries.  This protocol 
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follows current CDC recommendations. A link is provided to view countries with high 
TB burden for use as an additional reference.  
 The fifth comment suggested clarification to terminology used in the screening 
guidelines:  
Nothing to add. Needs more clarification however. Be sure to define terminology 
consistently. For example, define "lived in country where TB disease is common" 
consistently. Do you mean for one month or longer for all questions? Define 
health care worker?  IV drug use should be referred to as "persons who inject 
drugs."  Some persons should have serial testing if risk factors are still present, 
not just if new risk factors. 
 
Terminology in the screening guidelines was based upon CDC (2016) guidelines.  It 
would be helpful to provide a clearer definition of which countries experience TB more 
commonly and who to test based upon how long an individual resides in the country. 
Adding a precise definition for “health care worker” would be possible but would also 
add to the complexity of the tool.  It is possible to easily change the wording regarding IV 
drug use to persons who inject drugs.  
 The sixth comment suggested assessing pregnancy or future planned pregnancy: 
Is the person pregnant or planning to be pregnant?  Asking if a person is pregnant or 
planning to become pregnant is not currently a question recommended as part of the 
screening tool according to CDC (2016) guidelines.  Pregnancy might alter treatment 
decisions but might not affect the outcome of test results.  The tuberculin skin test and 
IGRA are safe to administer to pregnant persons.  Testing recommendations are available 
for pregnant persons through the CDC website.  
 The seventh comment suggested testing contacts of active TB cases:  Information 
about testing contacts to actives, and the recommendation for testing as soon as possible 
after exposure and the 8-10 week follow up testing.  The process of testing contacts to 
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active TB cases requires additional detailed information beyond what is currently 
included in the protocol.  Testing contacts to active cases of TB disease is important for 
avoiding spread of disease in the population.  Additional information regarding contact 
testing for individuals exposed active TB disease would be a good addition to the 
screening tool for providers participating in contact investigation testing.  
 The eighth comment was in response to updating testing information: QFT -Plus 
information, possibly adding to TST interpretation that one of the problems with reading 
of the test can be a very subjective.  The QuantiFERON Gold-Plus is the newest 
generation of IGRA test available by Qiagen corporation released in October 2017. 
Updating the protocol to include the most up to date test is appropriate and would be 
done prior to implementing the protocol in practice.  The participant stated the TST 
interpretation could be subjective so it would be important for clinical staff administering 
and interpreting TST results to be properly trained to avoid inaccurate results. This is 
stated in the protocol.  
 In response to the ninth comment (I would add the link for TST in 3D), an online 
TST and IGRA test result interpreter is available for use free of charge.  The tool was 
developed by researchers from McGill University Health Center (n.d.) in Montreal, 
Canada. The interpretation tool is supported by The Public Health Agency of Canada and 
the Stop TB Partnership (McGill University Health Center, n.d.).  The tool appears to be 
easy to access and use.  More research is needed to confirm whether this tool is evidence-
based and recommended for use.  Information about the TST/IGRA test result interpreter 
is available directly from McGill University Health Center’s website:  
The following tool estimates the risk of active tuberculosis for an individual with 
a tuberculin skin test reaction of ≥5mm, based on his/her clinical profile. It is 
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intended for adults tested with standard tuberculin (5 TU PPDS, or 2 TU RT-23) 
and/or a commercial Interferon Gamma release assay (IGRA). (p.1) 
 
Question Five: Recommendations for  
Additions to Testing Protocol 
 Survey question #5 assessed recommendations for additions to the TB testing 
protocol.  Seven comments/suggestions were provided by respondents. The first response 
suggested adding the IGRA test for individuals with a history of BCG vaccine and a 
positive TST: A second test - IGRA is indicated for TST-positive individuals from 
countries where BCG is used.  Many false-positive TSTs can be identified by IGRA 
testing.  The IGRA test is preferred for individuals with a history of BCG vaccine as 
indicated in the test selection protocol.  
 One comment suggested a more specific definition of risk for disease progression: 
Needs more clarification however.  For IGRA, define what is meant by "low or 
intermediate risk of disease progression."  Also, it is confusing to have "LTBI 
testing is recommended" only under the IGRA column.  Under table for 
performing both TST and IGRA, make it clearer that left column (Initial test 
negative) is likely referring to TST.  Also, IGRA is used in children under five 
years of age.  Look up a few published studies about that. 
 
Further definition of what is meant by low or intermediate risk of disease progression 
would be a helpful addition to the protocol.  Upon further investigation, it was difficult to 
find an exact definition of “low or intermediate risk of disease progression.”  The CDC 
(2017) recommendations focused upon testing individuals at high risk for progression to 
active TB disease: 
Most U.S. TB cases are associated with reactivation of longstanding, untreated 
latent TB infection. Testing for and treating latent TB infection in high-risk 
populations is the most effective way to prevent TB disease. Although anyone can 
get TB, some people have a higher risk of getting infected with TB germs, and 
should get tested for TB infection. These groups include: 




• People who currently, or used to, live in large group settings, such as 
homeless shelters or prisons and jails where TB is more common. 
• Health care workers and others who work in places at high risk for TB 
transmission, such as hospitals, homeless shelters, correctional facilities, 
nursing homes, and residential homes for people living with HIV. 
• Someone who has spent time with a person who has infectious TB disease. 
• Others with weaker immune systems, such as those with certain health 
conditions or taking certain medications, have a higher risk of developing 
TB disease once infected. (p. 1) 
 
It could be assumed that any group or individual not meeting the testing criteria might be 
at a lower risk of disease progression.  
 The participant also thought there was some confusion with part of the table under 
the IGRA testing section.  The statement “LTBI testing is recommended” is listed in the 
IGRA preferred test choice section of the test selection protocol.  It is possible to clarify 
this further by changing the phrase to “for any person recommended to receive LTBI 
testing.”  This same participant also suggested adding information to the algorithm better 
explaining why testing with both TST and IGRA would be recommended.  The 
participant assumed the initial test was a TST.  The chart does not assume the initial test 
is a TST because there is a possibility that the initial negative test could be an IGRA.  
 There was support by at least one subject matter expert in favor of testing children 
under age five with IGRA.  The most current guidelines have not yet confirmed nor 
adopted the IGRA test as recommended for children under age five at this time even 
though it is accepted by some in practice based upon recent research studies.  According 
to Adams and Starke (2017),  
There is insufficient evidence to support routine use of IGRAs in children <5 
years for evaluation of TB infection in the absence of symptoms. Some experts 
favor use of IGRAs to evaluate children ages 2 to 4, especially in the setting of 
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BCG vaccination. Most experts do not favor IGRA use in children <2 years due to 
insufficient data; TST is preferred in this age group. (Whom to test section) 
 
 Information about the QFT-Plus test was again recommended to be added to the 
protocol in survey question # 5.  As previously recommended, all components of the 
protocol need to be updated to the most currently recommended approved IGRA test.  It 
is uncertain precisely what the following response to question #5 referring to “At our 
agency, we also enter testing data for our patients into the TST” would be as 
documentation of testing data would be specific to clinic policy.  It would not be 
necessary to add a recommendation for data entry in the protocol. 
Question Six: Suggestions for Additions 
To Result Guidelines 
 
 Six total comments were made suggesting additions to the TB result guidelines 
section of the protocol.  One participant recommended adding more information to the 
protocol regarding false positive tests in U.S. healthcare workers: A bit more on false 
positives. US health care workers are now low-risk for TB and most positives without 
prior exposure are false positives.  Adding more information regarding healthcare worker 
risk for TB and potential false positive tests would require further investigation by the 
provider.  The TB result guidelines are designed to be a simple point-of-care tool.  Links 
to access additional information are provided.  Other than updating the testing 
information to reflect the new QFT-Plus test, the remainder of the subject matter experts 






Questions Seven, Eight, and Nine:  
Omitting Information from  
Protocol 
 
 Survey questions #7, #8, and #9 asked participants to suggest omissions from the 
TB screening tool, testing protocol, and TB test result guidelines.  Two suggestions were 
offered for omissions from the screening tool.  One participant suggested not 
recommending screening all individuals with diabetes: I don’t think screening all 
diabetics is indicated without TB exposure risk.  Diabetes mellitus increases the risk for 
progression from LTBI to active TB disease.  According to the CDC (2000), it is 
appropriate to test populations with diabetes for LTBI.  Additionally, changes were 
recommended for the TB test result guidelines to test all populations who recently arrived 
from medium and high burden countries; one participant suggested not including 
recommendations for testing populations from most Latin American countries since 
Brazil is the only country listed as a high burden country: As noted ALL of Latin America 
is not HBC only one country is on lists--BRAZIL.  The entire protocol was developed with 
the most currently available screening and testing guidelines from the CDC (2016).  Most 
participants had no suggestions for omitting information from the three sections of the 
protocol.   
Questions # 10, #11, and #12:  
Case Examples 
 
 Questions #10, #11, and #12 provided three different case examples for 
participants to review.  Each case example represented a different clinical scenario for a 
fictitious individual with risk factors for TB.  The participants were asked to utilize the 
TB protocol to determine whether the patient should be tested.  It also asked which test 
the participant would choose based upon what was offered in their clinic setting and why 
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that specific test was chosen.  Appendix E provides specific details regarding the case 
examples. 
 For question #10, of 15 responses received, 14 chose IGRA as the test of choice.  
This demonstrated accuracy and consistency with use of the protocol.  Most participants 
agreed the IGRA was a better test choice to avoid a potential false positive response with 
the TST since the patient had a history of receiving the BCG vaccine.  Interestingly, one 
participant did not feel it was appropriate to utilize the protocol for answering the case 
example question since the participants were already subject matter experts.  
 Of the 14 responses to the case example in question #11, six participants chose 
the IGRA test, seven chose the TST, and one chose both.  The protocol recommended 
tuberculin skin testing for children under five years of age.  Some clinicians chose to use 
the IGRA based upon more recent recommendations to do so.  As previously stated, there 
are no current formal recommendations in favor of performing IGRA testing for children 
under age five (Adams & Starke, 2017).  If IGRA testing is recommended for children 
under age five in the future, the protocol would need to be updated to reflect that 
recommendation.   
 Thirteen total responses were given to the case example in question #12.  The test 
selection protocol stated the IGRA is the preferred test of choice assuming the individual 
should be tested.  A TST is also an acceptable test for individuals.  Significant variations 
existed in the participants’ test choice for this case example.  It is possible more specific 
information should have been added to the case study including country of travel and 
whether baseline testing was done prior to travel.  While there was no right or wrong 
answer to this case example question, responses were sought to test use of the protocol. 
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Clinical expertise and professional judgement were used as an adjunct to the tool in 
answering this question by some participants rather than just answering the question 
based upon the protocol’s recommendations.  Two participants indicated either test might 
be used but IGRA would be preferred over TST.  Five total participants stated the IGRA 
was the better test choice, while three participants would use the TST.  One participant 
choosing the TST also added he/she would send the patient for a chest x-ray in addition 
to the TST.  One participant would use both tests even though it was not indicated 
initially for testing based upon the protocol.  Two participants stated they would not test, 
while one stated they would wait 8-10 weeks after travel before testing.  
Questions #13 and 14: Usefulness of 
Protocol in Public Health and  
Community Health Settings 
 
 Questions #13 and #14 asked participants if they thought the protocol would be 
useful in the public health and community health settings and to comment why or why 
not.  Sixteen total responses were received.  Twelve agreed it would be useful and four 
disagreed.  Those agreeing the protocol would be useful stated the protocol would be 
user-friendly in the clinic setting; the protocol is a clear guideline; it increases awareness 
of TB prevalence and risk for progression; it is simple and easy to use; it works well for 
rural clinics where TB testing is not done as frequently; and it reminds providers to think 
about TB.  Two participants mentioned cost and insurance coverage for IGRA testing 
might affect the test choice, which would be a potential barrier to increasing appropriate 
testing. Those who felt the protocol would not increase appropriate TB testing stated the 
protocol was unorganized, inaccurate, and missing information; public health already has 
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similar tools available; and it might not increase testing but might improve quality of 
testing.  
Questions #15 and #16: Usefulness of 
Protocol in Primary Care Setting 
 
 Questions #15 and #16 asked about potential for increased appropriateness of TB 
testing in the primary care setting.  Of 16 total responses, 13 stated the protocol would 
increase appropriate testing in the primary care clinic.  Negative comments indicated the 
tool was not well organized; it had inaccurate and missing information; it lacked 
incentives; there was lack of knowledge and lack of properly trained staff; and providers 
were hesitant to treat LTBI in primary care.  One comment stated primary care settings 
saw more patients with health insurance, which might affect how testing was done. 
Comments in favor of increased appropriateness of testing in primary care included clear 
guidance, concrete guidelines, increased awareness of TB and TB testing, ease of use, 
standards for testing, clinical clarification, improved approach to testing, and served as a 
reminder to assess for TB risk factors. 
Questions #17, #18, and #19: Profession  
of Experts, Work Settings, and  
Experience with Tuberculosis  
Screening and Testing 
 
 The purpose of questions #17, #18, and #19 were to collect demographic 
information of the subject-matter experts.  Professions (question #17) included registered 
nurses, physicians, one medical assistant, a community health promoter, and 
epidemiologists.  As noted in the results section, all participants except one reported 
working in public health departments and one participant reported working in a 
community health clinic.  Most participants had more than five years of TB clinical 
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experience, confirming the participants had knowledge and training in TB clinical 
activities. 
 Fifteen participants reported working in public health departments and one 
worked in a community health clinic (question #18).  The survey was sent out to public 
health and community health agencies to seek expert opinion in reviewing the protocol.  
 Fourteen of 15 participants who answered question #19 had experience with TB 
screening and testing.  Six participants had five years or less of experience, nine had 
more than five years of experience, and five had 10 years or more experience, thus 
confirming the respondents were subject-matter experts.  
Evaluation 
 The objective of this DNP project was to design and evaluate a clinical protocol 
for TB screening and testing to be utilized at the point-of-care. Intended clinics for 
utilization of the TB clinical protocol in the future included public health, community 
health, and primary care clinics.  The protocol was designed to aid in clinical decision-
making that was efficient, effective, and evidence-based.  It was important to include the 
ability to identify risk factors for TB indicating need for testing, recommended test type, 
and how to interpret test results.  The objective was achieved as all desired elements were 
included the clinical protocol, which was based upon the most recent testing guidelines 
available.  
 Protocol information was categorized into three sections: tuberculosis screening 
questionnaire and guidelines, a test selection protocol, and interpretation of test results; 
although designed to be used together, they might also be used separately.  The algorithm 
created for test choice was a simple, easy-to use-chart.  The algorithm could easily be 
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updated to accommodate new recommendations and provider or clinic preferences, thus 
accommodating individual needs for protocol organization.  
 Clinical experts in TB screening and testing evaluated the protocol and provided 
feedback through an online Qualtrics survey (see Appendix E).  An average of 79.6% of 
the participants strongly agreed, agreed, or somewhat agreed the entire protocol including 
all three sections was effective.  The guidelines for interpreting results scored lowest in 
effectiveness with 76.2% respondents agreeing.  The strongest area of agreement was that 
85% stated the entire protocol was evidence-based by strongly agreeing, agreeing, or 
somewhat agreeing.  Clinical efficiency scored the lowest overall with an average of 
76.5% strongly agreeing, agreeing, or somewhat agreeing that the protocol was efficient 
for clinical use.  
 The survey assessed recommended additions and omissions from the protocol by 
the subject matter experts.  Rationale for this evaluation supported potential protocol 
modifications to improve efficiency, effectiveness, and evidence-based content.  Each 
recommendation was reviewed and responded to following the comments in the results 
and outcomes section of this chapter.  Comments were received seeking additional 
clarification regarding geographic locations of birth country to assess risk for testing. 
Additionally, suggestions were received to clarify and update terms and/or phrases 
written in the protocol.  Terminology used in the protocol was adopted from the most 
current guidelines used in the United States from the CDC (2016) but could be easily 
modified to meet the needs of individual clinics.  One necessary update to the protocol 
included the most recently approved IGRA test--the QFT-Plus. It was also recommended 
that a link to the TST in 3D web site be added as a clinical tool for TB testing.  This 
35 
 
could be added to the protocol by clinics utilizing the tool.  More research needs to be 
done to evaluate the tool for evidence-based practicality.  
 The survey assessed validity of protocol effectiveness through three case example 
questions.  The case examples included different patient scenarios for participants to 
review.  Participants were asked whether testing was indicated and which test they would 
choose based upon what their specific clinic would offer.  The patient in the first case 
study question was an adult with a history of BCG vaccination.  All participants chose the 
IGRA test as recommended in the protocol.  This case study question validated the 
protocol’s effectiveness. 
 The second case study was a child under age five.  Many participants chose the 
IGRA test rather than TST for this patient based upon recent literature available 
supporting use of IGRA in this population.  The protocol recommended use of TST in 
children under age five, which was based upon most current evidence-based 
recommendations.  Perhaps recommendations in favor of testing children under age five 
with IGRA will change in the future based upon more recent studies.  While some 
participants chose the TST as the protocol suggested, others felt the IGRA was preferred 
and chose not to follow the protocol as written. 
 The third case example evaluated a college student with a recent history of travel. 
It is important to note that more information needs to be added to this example including 
exact geographic location of travel.  It was assumed the student needed to be tested since 
the student was exposed to a population with increased risk factors for acquiring TB 
infection and disease.  All but one participant stated the student should be tested and both 
tests were chosen equally by the participants based upon what they would use in their 
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clinics.  This case study was accurate with the suggestions in the testing protocol, also 
proving protocol effectiveness.  
 The survey also asked participants’ professional opinions about usefulness of the 
survey in both public/community health and primary care practice settings.  The purpose 
of this question was to assess efficiency of use in the clinic setting and to seek 
confirmation that the protocol was necessary.  Most participants (75% and 81%, 
respectively) stated the survey would be useful in both settings.  Comments in favor of 
usefulness included clear guidance and ease of use.  Comments against the usefulness 
included inorganized/inaccurate information and that tools like this were already being 
used in the public health setting so it might be more useful in primary care.  
 Demographic information collected in the protocol evaluated the amount of TB 
clinical experience and profession of the survey participants.  It was important to gain 
this information to confirm participants had some TB clinical knowledge and experience.  
Eleven of the 16 participants had two or more years of TB clinical experience and five 
participants had two years or less experience.  Ten participants were registered nurses; 
other participants included epidemiologists, physicians, medical assistants, and a 
community health promoter.  All participants worked in health departments or 
community health clinics.  
Key Facilitators 
 Successful outcomes for the development of an efficient, effective, and evidence-
based TB clinical protocol depended upon this researcher’s ability to identify the 
problem.  For this project, a need to develop a user-friendly tool was identified and 
supported through the literature review.  The literature review revealed much information 
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existed for clinical decision-making regarding TB screening and testing; however, a 
simple point-of-care tool was not found.  Thus, the literature review served as a key 
facilitator for this DNP project.  
 Development of partnerships is one of five criteria necessary to meet the 
outcomes of a successful doctoral nursing project (Waldrop, Caruso, Fuchs, & Hypes, 
2014).  Intraprofessional collaboration requires use of resources provided by nursing 
faculty and clinical nurse staff (Moran, Burson, & Conrad, 2017).  Nursing faculty 
members served as a guide for this researcher while clinical nursing staff served as 
subject matter experts in review and evaluation of the project.  Interprofessional 
collaboration outside the discipline included public health experts in epidemiology, 
administration, physicians, and other clinical staff with experience in TB testing.  Moran 
et al. (2017) shared several models supportive of interprofessional collaboration and its 
importance in improving healthcare outcomes.  Interprofessional and intraprofessional 
collaboration among the researcher, scholarly faculty at the University of Northern 
Colorado, TB elimination work group, and the CDPHE (2017) was the main key 
facilitator that made this objective achievable.  The researcher collaborated with both 
faculty and professionals having knowledge, expertise, and common goals related to TB 
prevention activities.  
 In December 2016, the Volunteer TB Elimination Planning Task Force presented 
a 10-year plan to eliminate tuberculosis in Colorado.  This elimination plan served as a 
facilitator for development of the TB clinical protocol.  Six goals were developed along 
with strategies and objectives to support elimination of TB statewide.  Goal two 
specifically addressed the need to test individuals at risk for TB.  Activities related to 
38 
 
development of a screening tool and standardizing use of IGRA testing.  The task force 
also sought to provide communication strategies with medical providers in the fifth goal. 
The first objective for this goal was to “develop and implement a strategy promoting 
clear and simple guidelines for screening, testing and treatment of TB infection” 
(Volunteer TB Elimination Planning Task Force, 2016, p. 17).  An activity for this 
strategy was to facilitate implementation of the screening/risk assessment tool and 
provide a toolkit to providers (Volunteer TB Elimination Planning Task Force, 2016). 
The group had previously developed a screening and risk assessment tool; however, this 
project expanded upon that tool by adding evidence-based information for use of IGRA 
testing, appropriate test choice in the test selection protocol, and a set of guidelines for 
test interpretation.  This project could be used with all three sections together or 
individual sections as needed for inclusion in a provider toolkit.  
 Recommendations for diagnosing TB in adults and children were introduced in 
January 2017 by the American Thoracic Society, Infectious Diseases Society of America, 
and The Centers for Disease Control and Prevention (Lewinsohn et al., 2017).  This 
served as a facilitator for developing the protocol testing recommendations.  The 
guidelines served as the most current information available for TB diagnosis and were 
utilized in the clinical protocol.  The new guidelines supported use of IGRA testing as a 
standard of practice.   
 Use of the nursing process was another key facilitator to formulating and 
developing the objective.  The assessment phase of the nursing process expanded upon 
information obtained in development of the identified need for developing the clinical 
protocol.  The TB elimination task force strategies were used to assist with defining the 
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project objective.  Diagnosis was the phase of the nursing process where data obtained 
through the literature review assisted with developing the need for the protocol.  The 
planning phase included a significant amount of time developing ideas for creation of the 
project.  Evaluation of the project collected information from the survey results and 
dissemination of the outcomes for future projects (Moran et al., 2017). 
 The Stetler (2001) model of research utilization served as the facilitator for the 
objective by assisting with closing the gap between evidence-based research and practice 
through transformation of research into practice.  Similar but also different than the 
nursing process, the Stetler model has five phases: preparation, validation, comparative 
evaluation/decision making, translation/application, and evaluation.  Chapter III 
described how the Stetler model was used in more detail.  The model was versatile for 
protocol development.   
 Additional facilitators for meeting the objective included a minimal budget 
beyond time invested by the student, slight to no risk for volunteer participants, and 
easily obtainable technology for protocol and survey development.  Without these 
facilitators, project delays and complications would have been inevitable.  
Key Barriers 
 The DNP proposal required revisions to create a practical project.  The project 
timeline was affected by the researcher’s need to revise the proposal frequently as the 
project was designed.  Initially, implementation of the project in the clinic setting was 
planned.  A decision was then made to change the project to an expert review of the 
protocol with the possibly of future implementation in the clinic setting.  This process 
allowed the researcher to seek feedback from subject matter experts to determine the 
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potential efficiency, effectiveness, and evidence-based content of the protocol.  It also 
allowed for recommended modifications to be made prior to future implementation in the 
clinic setting.  Additional revisions were made to the project, thus affecting timeliness 
related to the newly published guidelines by the Infectious Diseases Society of America 
in 2017 (Lewinsohn et al., 2017).  Time delays were a key barrier during this process.  
 The literature review revealed an abundance of information available to providers 
for TB screening and testing.  Developing a comprehensive tool that was simple to use at 
the point-of-care served as a challenge in meeting the objective.  A few comments 
received regarding additions to the protocol would have led to a longer, more 
cumbersome protocol and a less efficient point-of-care guide.  To proactively address this 
concern, links were added to the protocol for the provider to look up additional 
information if needed.  One survey comment addressed this well: the provider may “dig 
deeper” for additional resources as necessary.  
 The key barrier to protocol development was professional decisions might 
overrule protocol as was proven in the case examples.  Choices were made in the survey 
case studies by some participants that differed from recommendations in the protocol. 
Professional opinion beyond commonly available testing recommendations was used by 
some clinicians.  For example, one subject matter expert recommended reviewing more 
recent studies for use of IGRA testing in children under age five.  While evidence-based 
studies might be available, the most recent CDC (2017) guidelines do not yet recommend 
use of the IGRA in children under five.  
 Comments received from subject matter experts identified potential barriers for 
use of the protocol beyond professional clinical decision-making.  It was anticipated that 
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cost would be a contributing factor in test choice during protocol development.  While 
cost was not directly discussed in the responses, patient insurance coverage might force 
clinicians to choose one test over another even if it was not the most preferred test.  Staff 
must be properly trained to perform both the IGRA and TST, which could be a problem 
for some clinics.  Providers might not be aware of who to screen, were unfamiliar with 
treatment for LTBI, or felt no incentive for screening and testing.  These factors were not 
key barriers for development of this protocol but could be potential barriers for success 
with future clinical effectiveness and efficiency. 
 Finally, a key barrier in the collection of data was a low response rate to the 
survey.  The goal for survey responses was less than expected with 25 responses of 229 
e-mail invitations to participate--a 10.9% participation rate.  The survey was delivered on 
October 18, 2017.  The link to the survey remained open for more than three weeks until 
November 10, 2017.  A reminder e-mail for participation was sent on October 30, 2017. 
For unknown reasons, only 15-16 subject matter experts answered most questions by the 
end of the survey.  More information would have been collected if everyone had 
completed the survey.  
Unintended Consequences 
 A positive unintended consequence of the project was the ability to participate in 
an opportunity to partially meet objectives for the TB elimination plan in Colorado.  
Once the problem statement was decided upon, the researcher contacted the state TB 
epidemiologist to request advisement and support for the project (CDPHE, 2017).  
Introduction to the Volunteer TB Elimination Planning Task Force (2016) and the TB 
elimination plan were offered.  Development of a project to align with the goals and 
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objectives written in the TB elimination plan was an opportunity to bridge the scholarly 
project with a tangible plan for public health prevention activities.  
 A negative unexpected consequence was the need to update the protocol prior to 
implementation in practice.  In October 2017 a newer version of the IGRA test was 
introduced by Qiagen--the QFT-Plus.  The protocol would need to be modified with the 
latest approved tests prior to moving forward with future phases.  Modifications to the 
protocol are easily made but the protocol must continually be reviewed and updated as 
changes are recommended.  It would be important to identify practical ways to provide 
updates as needed to providers utilizing the protocol. 
 Both positive and negative unintended consequences were received from subject 
matter experts about accepting the protocol for clinical use.  Most supported use of this 
simple protocol in the clinic setting.  Responses in favor of or against utilization of the 
protocol were unknown prior to sending it out for review so a mostly favorable response 
was truly a positive consequence for the project.  One comment received created an idea 
that simply having a TB screening and testing protocol available would raise TB 
awareness by serving as a reminder to screen patients for TB risk factors and test patients 
at risk for TB.  Negative unintended consequences revealed potential barriers to future 
implementation of the project.  There was concern that staff might not be appropriately 



















 This chapter contains final recommendations and implications for practice. 
Several key facilitators and key barriers contributed to successes and challenges of the 
project development and outcomes.  Recommendations are included in support of key 
facilitators while potential solutions for key barriers are addressed along with 
recommendations for identified unintended consequences of the project.  Suggestions are 
provided for ongoing evaluation of the clinical protocol beyond the conclusion of this 
project.  Additional settings for project application are discussed.  Personal leadership 
goals for the DNP graduate including how this doctoral nursing project met the essentials 
of DNP education are provided in this chapter as well.  
Recommendations 
 The problem statement identified issues contributing to provider challenges with 
TB screening and testing including diversities amongst recommendations, the focus only 
on specific populations, and unique patient situations in the literature.  The opportunity 
existed to create an evidence-based protocol for improved and efficient clinical decision-
making at the point of care.  Recommendations for the problem statement remained to 
improve the quality of patient care and clinical efficiency with use of the TB protocol.  
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 The CDPHE (2017) TB program served as the lead supporting organization for 
this project.  The TB program manager was very supportive and was a connection to 
subject matter experts statewide.  Recommendations for the site include continued pursuit 
toward TB elimination in Colorado by working toward meeting the objectives as written 
in the strategic plan.  Continued work with graduate students interested in TB prevention 
might maintain momentum with the volunteer task force.  
 Key stakeholders were public health, community health, and primary care clinics 
with access to patient populations at risk for latent TB infection and active disease. 
Recommendations for key stakeholders are to implement this protocol in the clinic setting 
to increase testing for populations at risk and increase awareness of the importance of TB 
prevention.  
 The university setting offers a great opportunity for graduate nursing students to 
bridge the gap between scholarly work and clinical practice.  Many opportunities are 
available for the DNP student interested in population health to create clinical protocols 
for population health prevention activities including communicable diseases like TB.  
Connections with organizations such as state health departments persuade the health and 
safety of populations.  It is recommended that schools of nursing encourage doctoral 
students to reach out to these organizations in support of scholarly projects.  
 Recommendations for the DNP student would be to narrow the focus of the 
project and consider how projects should be developed in phases over time.  The original 
plans included testing the protocol in the clinic setting but it would be best to receive 
subject matter expert feedback prior to live testing in the clinic.  Waiting to implement 
the protocol for a future project is a good choice while offering the option to update and 
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improve upon the protocol, which would lead to a greater chance of success in the 
clinical setting.  
 Recommendations and implications for practice exist for key facilitators.  The 
scholarly literature review provided a baseline for identifying the opportunity to develop 
the protocol.  It is recommended that an ongoing literature review be conducted 
throughout the process to ensure the project is up to date with the most current 
information.  
 Collaboration with key stakeholders was an important facilitator for success when 
developing and meeting the objective.  Collaboration also facilitated success with current 
and future phases of the project.  Ongoing collaboration with the volunteer task force is 
recommended to move forward with the next phase of the project.  Members of the task 
force are experts in the profession and have great influence in promoting TB awareness, 
increasing screening and testing, and supporting recommendations.  
 The Stetler (2001) model of research utilization along with the nursing process 
facilitated forward movement of the project while allowing for continuous evaluation and 
flexibility for transformation.  The Stetler model provided flexibility and supported 
utilization of research into evidence-based practice.  Preparation, validation, decision-
making, translation/application, and evaluation might be either formal or informal in 
nature.  It is recommended that use of this model be continued as a guide for future work 
on the project.  
 A minimal budget was planned for this project, which primarily involved the cost 
of time spent by the DNP student.  A larger budget that included costs of professional 
assistance with survey development and providing an incentive might have resulted in a 
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greater response to the survey.  A greater number of responses might have led to 
additional recommendations for the protocol.  Moving forward, offering an incentive for 
clinics and providers to test the protocol in practice is recommended.  The incentive 
might include a small gift of appreciation such as gift card or perhaps a meal could be 
furnished to providers along with an educational session about use of the tool in practice.  
 Modern technology was a great facilitator for protocol development, online 
surveys, and communication with stakeholders.  In the future, it would be essential to 
collaborate with computer professionals to add protocol access in electronic health 
records.  The paper format is useful during development but providers rely on electronic 
devices for access to records and clinical resources.  Integrating the protocol into 
electronic health systems once it is implemented in the practice setting would increase 
access at the point of care.   
 Recommendations for identified barriers to meeting the objective include 
reducing time spent on revisions, reviewing literature regarding IGRA testing in children 
under age five, adding more links for additional testing information, considering test cost 
and insurance coverage, and identifying ways to improve survey participation.  Time 
spent revising the project was stretched out over several months, which led to research 
advisors and the DNP student to refamiliarize themselves with the details over time. 
Improvements with time management would lead to smoother flow with both proposal 
writing and protocol development.  
 Interferon gamma release assay testing for children under the age of five is not 
currently recommended; however, subject matter experts were relying on more recent 
studies for clinical decision-making for TB testing.  It would be recommended to conduct 
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an additional literature review of the topic in anticipation of changes to future testing 
recommendations for children under age five.  
 The protocol recommended use of tuberculin skin testing as an acceptable 
alternative when IGRA is too costly.  While insurance coverage and cost are factors in 
test choice, the protocol addressed an acceptable alternative.  No additional 
recommendations are currently proposed so decisions will continue to be based upon 
agreements made between the provider and patient given the patient’s unique situation.  
 Several factors were identified affecting survey response rates.  A systematic 
review by Fan and Yan (2010) examined challenges with web surveys contributing to 
low response rates.  Factors in survey development include survey content and 
presentation.  Factors in delivery include sampling error in that not all participants have 
access to the survey, modes of delivery, design of the invitations, use of pre-notifications 
and reminders, and incentives.  Factors affecting completion response rates include 
theories about decision to participate.  Factors affecting response rates when returning the 
survey include software product used and data safety (Fan & Yan, 2010).  In taking a 
closer look at the present survey, many participants started the survey but did not 
complete all the questions.  Based upon recommendations by Fan and Yan, future 
surveys should involve expert design to maximize responses.  Additionally, the survey 
was sent to a large contact list with a lengthy invitation.  Improvements to the invitation 
design might improve response rates along with a pre-notification of the upcoming 
protocol and survey.  It is also important to consider potential issues such as technical 
challenges limiting access to and receipt of the survey.  
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 Continued progress and success with the TB clinical protocol will be dependent 
upon continued support by the Volunteer TB Elimination Planning Task Force (2016).  It 
would be important to align future phases of the project with the objectives and activities 
identified by the organization’s strategic plan.  As written in the plan’s executive 
summary, TB control is challenging but new technologies are improving the way TB is 
diagnosed and treated.  Work must continue to support efforts toward TB elimination 
(Volunteer TB Elimination Planning Task Force, 2016).  Success with future protocol use 
will be dependent upon general upkeep and maintenance with most recent testing 
technology and evidence-based recommendations. A plan needs to be made to address 
updates and method of delivery to providers.  
 The researcher recommends this project be continued.  Next steps include clinical 
updating of the protocol based upon expert recommendations and implementation at 
point of care. Continued collaboration with the state health department and task force 
would assist with locating volunteer settings for testing the protocol in the clinical setting.  
Additionally, it will be important for providers to have electronic access to the protocol 
so additional stakeholders must be added to the project for technological assistance.  
Decisions will need to be made regarding who will be responsible for updating the 
protocol in the future. 
Ongoing Evaluations 
 Evaluating success of the clinical protocol in the practice setting will be important 
beyond the scope of this DNP project.  Clinicians and administrators will be responsible 
for monitoring the effectiveness, efficiency, and evidence-based content of the protocol 
in the practice setting.  This might be done through data mining of electronic records at 
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the clinical site to evaluate appropriate screening and testing of patients at risk for TB.  
Clinics will need to develop goals, objectives, and activities to support such ongoing 
evaluation.  The TB elimination strategic plan has a goal to support tracking and 
evaluation of programs to measure progress of integrating new technologies (Volunteer 
TB Elimination Planning Task Force, 2016).  Public health and community health 
providers will be responsible for providing support, education, communication, and 
disease monitoring at the population level in response to future phases of the project.  
Recommendations for Project Application  
in Other Settings 
 Any setting with populations at high-risk for TB would be able to utilize the 
protocol.  Correctional facilities, university health clinics, homeless shelters, and mobile 
health vans providing care to underserved populations would be ideal settings for project 
application beyond public health departments, community health centers, and primary 
care clinics.  These settings should be screening for and testing individuals for TB risk 
factors.  Public health authorities would be responsible for identifying settings with high- 
risk populations and providing education and toolkits for successful screening and testing 
programs.  The clinical protocol should be part of that toolkit.  
Personal Leadership Goals 
 As a DNP graduate student, personal leadership goals included gaining the 
knowledge and skills to bridge the gap between theory and clinical practice.  The DNP 
graduate program is designed for the student to successfully comprehend all the elements 
of the scholarly project and assemble them into a final scholarly work designed for 
practical use.  The ultimate result of combining scholarly work with practice should 
contribute to improvements in health care and increase knowledge in a specialty area 
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(Moran et al., 2017).  This project prepared the student to identify quality articles, 
research best evidence for practice, identify an opportunity, and develop a project that 
will improve population health care outcomes that align with current strategic plans.  
 It was important for this DNP graduate to provide leadership within 
interprofessional teams.  Experience gained with collaboration with university faculty, 
public health, nursing, and primary care provided the skill set needed for leadership in an 
advanced health care profession.  The National Center for Healthcare Leadership (2017) 
strives to improve health care through leadership and organizational excellence.  Creating 
collaboration was a main objective along with creating a base of evidence for optimizing 
leadership in healthcare.  Quality health care relies on the ability for professionals to 
work together across many disciplines, which met this professional leadership goal.  
Essentials of Doctor of Nursing Practice Education 
 Doctor of Nursing Practice education consists of eight essentials for doctoral 
education developed by the American Association of Colleges of Nursing (AACN;  
2006).  The following section explains the eight essentials along with how this project 
met each item.  
Essential I: Scientific Underpinnings  
for Practice 
 This essential expectation is best described by the DNP educated advanced 
practice nurse when demonstrating understanding of complexities of practice.  It is 
important for the DNP student to effectively translate knowledge to practice.  
Preparations for meeting this essential include integrating nursing science with a variety 
of other sciences, use theory and concepts to improve health care delivery, and develop 
new approaches to healthcare delivery through application of theory (AACN, 2006). 
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Development of a new clinical protocol for TB screening and testing met the 
requirements for this first essential.  Knowledge regarding TB screening and testing was 
obtained through combined nursing clinical experience and a review of literature.  The 
Stetler (2001) model was utilized to facilitate development of the evidence-based 
protocol derived from the research findings in the literature review.  Healthcare delivery 
will be improved through use of this effective, efficient, and evidence-based project.  
Essential II: Organizational and Systems  
Leadership for Quality Improvement  
and Systems Thinking 
 To best summarize this essential, DNP prepared graduates must understand 
organizations and systems leadership to improve health outcomes in populations.  This 
essential extends beyond direct patient care into having the skills to work on strategies for 
quality improvement in the health care setting (AACN, 2006).  This scholarly project met 
Essential II by the development of a protocol that not only assisted with clinical care 
activities but also aligned with the strategic plan to eliminate TB in the population.  The 
population at risk for TB requires much sensitivity, working within a limited budget 
(many volunteer hours from professionals), and excellent communication skills for 
success.  
Essential III: Clinical Scholarship and  
Analytical Methods for Evidence- 
Based Practice 
 This essential is best summarized as successful application of scholarship into 
practice.  According to the AACN (2006), this also includes the ability to evaluate 
practice, improve outcomes, and participate in research.  The objective for this project 
was to develop a useful protocol based upon research that was applicable to practice, 
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which met Essential III.  Additionally, a thorough evaluation of the protocol was 
achieved through an online survey and collaboration with subject matter experts.  The 
protocol was designed to improve quality of care that was effective, efficient, and 
evidence-based.  Findings of the survey were intended to lead to developing a quality 
product for use in practice.  
Essential IV: Information Systems/ 
Technology and Patient Care  
Technology for the Improve- 
ment and Transformation  
of Health Care 
 
 This essential requires graduates to be proficient in the use of information systems 
and technology.  Five requirements are needed to meet the expectations: use of programs, 
analyzation of health care information systems, ability and technical skills for data 
extraction, leadership, and evaluation (AACN, 2006).  Use of technology during 
development of this project was abundant.  Technology was used to obtain and evaluate 
information.  An online survey was used to collect and evaluate data.  Communication 
networks including e-mail and phone conferencing were used to attend regular meetings 
to share and execute plans.  
Essential V: Health Care Policy for  
Advocacy in Health Care 
 Governmental involvement is important in creating, enforcing, and supporting 
healthcare policy to deliver healthcare services.  This essential required the DNP graduate 
student to assume a leadership role on behalf of the public and the profession.  Many 
issues are involved with delivery of health care (AACN, 2006).  Patients at risk for TB 
are culturally diverse and many have additional healthcare disparities contributing to 
increased risk.  Healthcare policy greatly influences the way TB is prevented and 
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controlled.  As a volunteer on the task force for TB elimination in Colorado and as a 
student willing to share the project with local government health agencies, the researcher 
met the requirements for Essential V.  
Essential VI: Interprofessional  
Collaboration for Improving  
Patient and Population  
Health Outcomes 
 The DNP graduate must be able to work effectively with multiple disciplines and 
exhibit appropriate leadership in teams (AACN, 2006).  Communication and 
collaboration with multiple teams was necessary for development of this protocol. 
Epidemiologists, program managers, providers, nurses, university faculty, and outreach 
workers were involved in providing feedback throughout the process.  The researcher 
provided leadership and guidance throughout the process by coordinating meetings and 
providing updates to advisors.  
Essential VII: Clinical Prevention and  
Population Health for Improving the   
Nation’s Health 
 Implementation of clinical prevention and population health activities summarizes 
this essential (AACN, 2006).  This DNP project was based upon goals to prevent and 
eliminate TB from the population at the state level.  The strategies for local population 
health are a part of a greater strategy developed by the WHO (2015) to eliminate TB.  
The DNP student extensively analyzed TB data as it related to population health and also 
developed a protocol to assist with screening and testing high-risk populations for TB. 






Essential VIII: Advanced Nursing  
Practice 
 This essential requires the DNP graduate prepare for advanced practice in a 
specialized area of nursing.  It is important to note that the essential provides a foundation 
for practice as a DNP.  Essential VIII is a culmination of skills required by essentials I 
through VII with application to practice.  The DNP must be able to assess health and 
illness in complex situations, provide therapeutic interventions, have therapeutic 
relationships, demonstrate advanced levels of clinical judgement and thinking, support 
and mentor other nurses, educate and guide others, and demonstrate strong analytical and 
conceptual skills (AACN, 2006).  This project aimed to design an evidence-based 
protocol with the goal of improving outcomes for patients and the TB population.  
Various clinical experiences in family practice were obtained throughout the program. 
Additionally, specialty TB clinical knowledge, nursing knowledge, and advanced 
analytical skills in population health issues were required to develop the TB protocol, 
thus meeting the requirement for Essential VIII.   
Summary 
 Clinical use of evidence-based tuberculosis testing technologies based upon 
newer recommendations released by the USPSTF in 2016 and the Infectious Diseases 
Society of America, Centers for Disease Control and Prevention and American Thoracic 
Society (Lewinsohn et al., 2017) provided an opportunity to create a new efficient, 
effective, and evidence-based TB screening and testing protocol.  Goals to eliminate TB 
both globally and locally supported increased screening and testing for individuals at high 
risk of TB.  Providers need assistance with clinical decision-making at the point-of-care 
to encourage appropriate TB screening and testing. The Stetler (2001) model of research 
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utilization served as a model to guide the project.  Development of the protocol aligned 
with the strategic plan to eliminate TB in Colorado (CDPHE, 2017).  Once the protocol 
was developed, expert feedback was received through a Qualtrics survey.  Most 
respondents agreed the protocol was efficient, effective and evidence-based.  Respondent 
comments were reviewed regarding recommended edits, omissions, and additions to the 
protocol.  Once the protocol is updated with the newest test and modified based upon 
expert suggestions, it will be ready for testing in practice.  This DNP project met the eight 
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Sample Method Results/other 
1995 Bloch, A. B.  Recommendations 
for screening for 
TB by the 
advisory council 
for the elimination 
of tuberculosis 
Expert Opinion  N/A N/A Provides CDC 
recommendations 
for identification of 
and screening high 
risk populations for 
TB 












8463 patients in 








Screening of high 
risk patients for 
LTBI increased from 
8.9% to 25.2% with 
the computerized 
clinical decision 
support tools which 
included alerts and 
guided web-based 
documentation.  




TST, QFT, and 
QFT-G in subjects 




148 subjects with 
suspected TB 
All subjects were 
tested with three 
tests 
simultaneously 
All 3 tests have 
similar sensitivity in 
subjects with culture 
confirmed TB, but 
negative tests should 
not be used to 
exclude diagnosis of 
TB in patients with 
symptoms of TB.  
 
         6
4
   
 
2007 Mazurek, 
Zajdowicz et al.  
 
Comparison of 
TST, QFT, and 







tested with TST, 




G (99.8%)and TST 
(99.1%) were higher 
than QFT (92.3%) 




change of TB 
blood test results 
during TB 
treatment 
Comparison study 48 patients with 
confirmed active 




and T-SPOT test 
were done, serial 
testing was done 
during treatment 
of the active TB 
subjects 
Both commercial 
blood tests were 
more useful than 
TST for patients 
with active TB, no 
significant 
differences between 
the two tests, several 
false negatives and 
indeterminate tests 




2009 Higuchi et al. 
 
Comparison of 
two TB blood 
tests for 
diagnosing TB 
Comparison study 47 patients with 







was 100% and QFT-
G sensitivity was 
87.2% in this study 
2010 Sester et al. 
 













IGRA are higher 
than TST, but IGRA 
should not be used 





      
 
2010 Mazerek et al.  Provide 
recommendations 
for use of IGRA  
Expert opinion N/A Literature review Provides 
recommendation for 
use of IGRA-newer 
guidelines have 
since been published 
2011 Linas et al.  Identify cost 
effective TB 
screening tests 
and estimate costs 






defined by CDC 
risk groups for 
TB, Data was 
retrieved from a 
large US 
database, cost of 
test varies by age 




This article is a 
comparison study 
between the TST 
and IGRA tests 
utilizing a Markov 
model to determine 
cost effectiveness of 
both TB tests in 
high risk 
populations. 
2011 Denkinger et al.   Identify diversity 















4 main approaches 
to TB testing 
recommendations 
exist (2-step, IGRA 
only, both TST and 
IGRA, either TST or 
IGRA-not both); 
overall increased 
use of IGRA’s but 
current guidelines 










2011 Horsburgh & 
Rubin  
Identify 
candidates for TB 
screening, select a 








This article is a 




based upon those 
guidelines 












TST were given 
to each 
participant 
In populations with 
a low prevalence of 
TB, there is not 
much difference in 
specificities in any 
of the three tests. 
TST (99.3%), QFT-
GIT (98.8%) and T-
SPOT(98.7%). 88 
subjects had positive 
tests, only 10 of 
these were positive 
to all three tests 
2013 Pareek et al.  Comparative 
performance and 
cost effectiveness 
of IGRA tests and 
TST test with and 
without chest x-










Cost analysis of 
IGRA and TST 
test  
CXR could be 
eliminated if IGRA 
testing is used 
which would be cost 



















clinical data of 
1301patients 
diagnosed with 





In patients with high 
inflammatory 
markers like CRP, or 
older age QFT-GIT 
results may have 
higher indeterminate 
or negative results 
2013 Painter et al. 
 
Compare 
sensitivity of QFT 





BCG vaccine at 
birth 
Comparison study 996 Viet Nam 
immigrants with 
abnormal chest 




QFT and TST 
results were 
obtained  
QFT is just as 
sensitive as TST in 
detecting TB in this 
population, fewer 
chest x-rays were 
necessary with QFT 
making QFT 
preferred test for 
this population 
2016 Olivieri et al.  Study of results of 
IGRA test in 
addition to TST in 
Italian health care 
workers 
Retrospective 






All subjects with 
initial positive 
TST test were 
tested with QFT-
GIT along with a 
group of TST 
negative subjects 
Use of QFT-GIT test 
as a second step is 
useful for detecting 
LTBI, especially in 
BCG vaccinated 
healthcare workers 
2016 USPSTF  Screening 
recommendations 
for adults at 
increased risk for 
tuberculosis 
Recommendations 
based on review 
of evidence 





Screen adults at 



























for LTBI were 
developed 






based on review 
of evidence 



































































































RECRUITMENT EMAIL, INSTITUTIONAL REVIEW BOARD 




Date: October 17, 2017 
 
Re: Evidence-based Tuberculosis Screening and Testing Clinical Protocol for Public 




I am writing to inform you about an opportunity to participate in a Doctorate of Nursing 
Practice capstone project reviewing a tuberculosis testing clinical protocol. You are being 
asked to complete a short online survey to provide feedback on the proposed protocol. 
The survey should take no more than 10 minutes of your time. The purpose of this project 
is to develop a clinical protocol for future use in both public health and primary care 
settings. 
This letter is being sent by the Colorado Department of Public Health and Environment 
(CDPHE) TB program on behalf of the graduate student, Kimberly Senn. Your 
participation in this research project is completely voluntary. You may decline altogether, 
or choose not to answer specific question(s). There are no known risks to participation in 
this project beyond those encountered in daily life. Your responses will remain 
confidential and anonymous. Data from this research will be reported only as a collective 
combined total. 
The protocol and survey may be accessed through attachments and a link provided in the 
e-mail (below). If you have any questions about this project, feel free to contact me via 
phone or e-mail. Your assistance with this project is greatly appreciated.   
Once you have reviewed the attached protocol, you may access the survey by 
clicking on the link below:  
TB Screening and Testing Protocol Survey 
 
Sincerely, 









Institutional Review Board 
CONSENT FORM FOR HUMAN PARTICIPANTS IN RESEARCH  
UNIVERSITY OF NORTHERN COLORADO 
Project Title: Evidence-based Tuberculosis Screening and Testing Clinical Protocol for 
Public Health and Primary Care Providers  
Researcher: Kimberly Senn, DNP Student Phone Number: (970) 371-2887  
E-mail: mill4151@bears.unco.edu 
Project Advisor: Jeanette McNeill Phone Number: (970) 351-1704  
E-mail: Jeanette.McNeill@unco.edu 
 
The purpose of this doctoral capstone project is to develop a point-of-care evidence-based 
clinical protocol. The protocol will assist public health, community health, and primary 
care providers with screening and testing for tuberculosis (TB) in adults and children. 
The protocol and link to the online survey will be e-mailed to participants with the 
assistance of the Colorado Department of Public Health and Environment TB program 
staff.  
 
Participants are being asked to complete an online survey providing feedback on the 
proposed protocol. Survey questions will assess the proposed protocol for effectiveness, 
efficiency, and evidence-based content. Participants are asked to provide minimal 
demographic information including profession (MD, RN, Administrator, etc.), work 
setting, and years of work experience with TB. Participants will not be asked to provide 
any personal identifying information. Data from this research will be reported only as a 
collective combined total. 
 
There are no known risks to participate in this project beyond those encountered in daily 
life. Responses will remain confidential and anonymous. Benefits to the participant 
include the opportunity to provide feedback on the development of a clinical protocol. 
This feedback may lead to improved evidence-based clinical practice for TB screening 
and testing in the future. 
 
Participation is voluntary. You may decide not to participate in this study and if you 
begin participation you may still decide to stop and withdraw at any time. Your decision 
will be respected and will not result in loss of benefits to which you are otherwise 
entitled. Having read the above and having had an opportunity to ask any questions, 
please complete the survey if you would like to participate in this research. By 
completing the survey, you will give us permission for your participation. You may keep 
this form for future reference. If you have any concerns about your selection or treatment 
as a research participant, please contact Sherry May, IRB Administrator, Office of 





















































The TB screening tool would 
increase effectiveness of TB 
testing in your clinic. 
     
The TB testing protocol will 
increase effectiveness of TB 
testing in your clinic. 
     
The TB test results guidelines 
will increase effectiveness of 
diagnosing Latent TB Infection 
in your clinic. 
     
Evidence-based  
The TB screening tool follows 
the most recent evidence-based 
guidelines. 
     
The TB testing protocol 
follows the most recent 
evidence-based guidelines. 
     
The TB test result guidelines 
follow the most recent 
evidence-based guidelines.  
     
Efficiency 
The TB screening tool would 
be efficient to use in the clinic 
setting. 
     
The TB testing protocol would 
be efficient to use in the clinic 
setting. 
     
The TB test result guidelines 
would be efficient to use in the 
clinic setting.  
     
 
What would you suggest adding to 
the TB screening tool? 
the TB testing protocol? 
the TB test result guidelines? 
 
 
What would you suggest omitting from 
the TB screening tool? 
the TB testing protocol? 
the TB test result guidelines? 
81 
 
Case examples: Please answer the following questions based utilizing the TB 
screening tool, protocol and test result guidelines. Choose the test that would most 
likely be offered in your clinic setting.  
 
1. A 49-year-old adult male born in Mexico visits your clinic for a diabetes follow-
up visit.  The patient has never been tested for TB. He remembers spending time 
with a family member with active TB as a child. The patient has a history of 
receiving BCG vaccine as a child. 
 
Would you recommend testing, and if so which test would you choose the TST or 
IGRA? 
 
Why would you choose this test? 
 
2. A 4-year-old female refugee from Somalia visits your clinic. The patient’s mother 
is currently being treated for active TB disease.  
 
Which test would you choose for this patient?  
 
Why would you choose this test?  
 
3. A 20-year-old male college student visits the campus clinic one month after 
travelling on a 3-month long medical mission trip working in a remote HIV clinic.  
 
Would you recommend testing for TB, and if so which test would you use? TST 
or IGRA? 
 
Why would you use this test? 
 
Additional questions:  
1. In your opinion, will these screening and testing protocols increase appropriate 
TB testing in the public/community health clinic setting? Yes  No 
 
Why or why not? 
2. Will these screening and testing protocols increase appropriate TB testing in the 
primary care clinic setting?   Yes  No 
 










1. What is your profession? 
 
o Registered Nurse 
o Physician 
o Medical Assistant 
o Other: _______________ 
 
2. What type setting do you work in (check all that apply)? 
 
o Public Health Clinic 
o Primary Care Clinic 
o Community Health Clinic 
o University Health Clinic 
o Specialty clinic _____________ 
o Other______________ 
 
3. How much experience do you have with TB screening and testing? 
 
o None 
o 0-2 years 
o 2-5 years 
o 5-10 years 
o More than 10 years 
 
 
 
